Investors swallow Glenmark debut despite tight pricing
Glenmark Pharmaceuticals sealed its debut $200m international bond at a yield of 4.5% on Monday, which bankers on the deal said was the tightest pricing achieved by an Indian high yield name.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts